Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. - Wikidata - awgldk - TriplyDB

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

http://www.wikidata.org/entity/Q34740245

about

Anti-vascular endothelial growth factor for diabetic macular oedema Current Challenges in Diabetic Retinopathy: Are We Really Doing Better?Updates on the Clinical Trials in Diabetic Macular Edema INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: PHARMACOKINETIC CONSIDERATIONS The clinical utility of aflibercept for diabetic macular edema Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)A review of anti-VEGF agents for proliferative diabetic retinopathy Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines Current perspectives on ranibizumab Diabetic macular oedema: evidence-based treatment recommendations for Asian countries.Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA.New Therapeutic Approaches in Diabetic Retinopathy.Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice.Prognostic factors of short-term outcomes of intravitreal ranibizumab in diabetic macular edema.A Review of Ranibizumab for the Treatment of Diabetic Retinopathy.Ranibizumab for the treatment of degenerative ocular conditions.Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis Advances in diabetic retinopathy.Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.Current concepts in diabetic retinopathy Diabetes-induced superoxide anion and breakdown of the blood-retinal barrier: role of the VEGF/uPAR pathway.Implantable MicroPump for Drug Delivery in Patients with Diabetic Macular Edema Anti-vascular endothelial growth factor therapy for diabetic macular edema Evolving strategies in the management of diabetic retinopathy Anti-VEGF for the management of diabetic macular edema.Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema: a meta-analysis of randomized controlled trials Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective.A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series Prognosis of patients with diabetic macular edema before Japanese approval of anti-vascular endothelial growth factor.Novel Therapies in Development for Diabetic Macular Edema.[Diabetic maculopathy].South Asian diabetic macular oedema treated with ranibizumab (ADMOR)-real-life experience.Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.

P2860

Q24193083-4B2D22EC-D57E-4811-BEAC-243481D7C91A Q26746083-F3BA10A4-CB6D-4D48-B277-C18C47ED88BD Q26767100-33308587-0188-4797-A19B-C9A003A5F11A Q26782198-79CB1476-3A04-40F5-AE81-62EB73BBF2CF Q26783575-67D74319-6088-4ADF-AE34-35E790DA5024 Q26786012-6E36F4ED-BA14-4205-A8D9-7D9ACD4CA322 Q26823985-841F0D3F-5370-4D24-AA3E-64EAC4811122 Q27025643-5FDD43B5-AE00-4024-9BAC-2BEB2241C9A2 Q28066675-0B90D8D0-A165-4E99-A2F6-AFADB9CB34A3 Q28075473-0F254135-D4A3-4434-ACA9-DF0D661FCBBD Q28082383-CB55A8FC-C26F-4F71-84E2-9D7C4B56C651 Q30101045-0A42A6C6-4DDA-4926-B7C5-D9C73D3E3D26 Q30244247-7F12DF70-7815-4708-87B7-5E317846FF2D Q30491050-4260DD9A-9461-4315-A1C1-58C8754F09E7 Q33583037-D41232A3-E38A-45B8-870B-948793E0D7E1 Q33606076-AE0095CF-2095-483E-A7DA-1B5F2887E368 Q33706098-9DD72E6E-5B3D-469A-913B-107939BE6C37 Q33740152-C6F14873-49CE-471A-B0E5-EA34DAAB5900 Q33831237-4E65D666-071D-4043-BC3E-8EC47F019820 Q33840787-8E1D8395-2D17-4D64-A13F-7465F060299B Q33910289-6A742285-5955-4DEC-B275-E29E56A6CD88 Q34319662-DEE060C4-D53B-4A14-8687-FD168614DFB2 Q34558187-81F1B23E-B690-448F-B71B-8389A9C47132 Q34750020-98E41F95-7C3E-41FA-AEC2-2A9BD6736927 Q34950799-65EC72F5-62CA-4A7D-A7F4-E261088808E5 Q35043903-393AF7A0-B8A6-4A85-B3C7-C2B9DEA3BAC2 Q35064343-43823782-D4BA-48F1-9F73-D9A994A6E936 Q35067102-5348BB4B-1FE9-4C48-B62C-610715BC7570 Q35151008-355AAF0B-40C8-4B4E-AD1D-CDB760174369 Q35171497-758AAD4A-9830-4857-839A-180CE332036F Q35534298-036632A7-3938-4A39-9061-91466F4E99F0 Q35559508-ADA1BAD7-68F4-459B-800C-1CE83822B0C7 Q35575496-11A9979E-3CCB-46ED-9B46-B7C761B84361 Q35592307-14B0DD1A-5A66-49AB-A04A-14057E56C9CE Q35592903-FB2C861B-1AE2-465D-9E06-DEC745E214F2 Q35640797-2F242F83-709D-4F5D-83C9-36B855BAA13B Q35751912-94E4DD61-74F8-466A-A024-97A7ACCF983D Q35792895-ADB206BA-C424-4D7F-957A-6397E171EFE4 Q35817666-56DE98AC-D38B-4C13-BC9B-E04571463209 Q35828114-A6C6DEBB-6459-4124-901A-B0B6EE132304

P2860

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

http://www.wikidata.org/entity/Q34740245

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Long-term outcomes of ranibizu ...... ase III trials: RISE and RIDE.

@ast

Long-term outcomes of ranibizu ...... ase III trials: RISE and RIDE.

@en

Long-term outcomes of ranibizu ...... ase III trials: RISE and RIDE.

@nl

type

label

Long-term outcomes of ranibizu ...... ase III trials: RISE and RIDE.

@ast

Long-term outcomes of ranibizu ...... ase III trials: RISE and RIDE.

@en

Long-term outcomes of ranibizu ...... ase III trials: RISE and RIDE.

@nl

prefLabel

Long-term outcomes of ranibizu ...... ase III trials: RISE and RIDE.

@ast

Long-term outcomes of ranibizu ...... ase III trials: RISE and RIDE.

@en

Long-term outcomes of ranibizu ...... ase III trials: RISE and RIDE.

@nl

P1433

Q34740245-B53226DB-CA5E-498F-BF8D-1640A60E2DF2

P1476

Q34740245-86B2B05A-DF54-44A7-B1B5-338957DE95D4

P2093

Q34740245-0CBCCE89-F01F-4F8F-921F-A8712487441E

Q34740245-10F3A816-D8BC-4045-AF66-56595F758267

Q34740245-28834F16-4682-466E-B1E4-14A2D842BB3A

Q34740245-30988DFE-EAF4-40AD-99A6-E27B3F6391E5

Q34740245-49C922D1-23D0-442C-A5A9-7EEC8D6DBF7A

Q34740245-59A673BF-1967-4ABD-9B75-91A28F5AC9AF

Q34740245-5ECF41E6-AA06-48A4-8E28-20C4211B935E

Q34740245-915E1033-D374-41B9-9525-D637E9753A48

Q34740245-A828DD36-C370-4728-88F9-5A7AE7B1DDDC

Q34740245-B3693E6F-97A1-4D9E-9EE5-C8F40A3DF134

P304

Q34740245-26339BE4-6727-441D-92E7-B110C2FDC57C

P31

Q34740245-12AA25BB-A158-4AD7-A96A-28E80A244769

P356

Q34740245-AD5D38EC-E3FE-4143-8822-764FF25F362F

P433

Q34740245-83828A17-0D60-4CFF-B4F2-5AFA6A3C061E

P478

Q34740245-9A4C3AA3-04B4-4E74-9A28-EFCF52276870

P577

Q34740245-411AD340-4909-4B63-A422-F97465BCF804

P5875

Q34740245-FE5DE305-A3AD-46EC-AA11-6169E31E4C58

P698

Q34740245-DD6FF791-A786-4289-BACE-2DC895093046

P921

Q34740245-2DD318F5-6FC7-4554-93AB-1C507EA29B3E

P356

J.OPHTHA.2013.02.034

P1433

P1476

Long-term outcomes of ranibizu ...... ase III trials: RISE and RIDE.

@en

P2093

Amy Chen Rundle

http://www.w3.org/2001/XMLSchema#string

Anthony P Adamis

http://www.w3.org/2001/XMLSchema#string

David M Brown

http://www.w3.org/2001/XMLSchema#string

David S Boyer

http://www.w3.org/2001/XMLSchema#string

Dennis M Marcus

http://www.w3.org/2001/XMLSchema#string

J Jill Hopkins

http://www.w3.org/2001/XMLSchema#string

Jason S Ehrlich

http://www.w3.org/2001/XMLSchema#string

Jiameng Zhang

http://www.w3.org/2001/XMLSchema#string

Leonard Feiner

http://www.w3.org/2001/XMLSchema#string

Patricio G Schlottmann

http://www.w3.org/2001/XMLSchema#string

P304

2013-2022

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OPHTHA.2013.02.034

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262043294

http://www.w3.org/2001/XMLSchema#string

P698

23706949

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial